Cell-Free DNA Blood Collection Tubes Are Appropriate for Clinical Proteomics: A Demonstration in Colorectal Cancer

Overview

Journal Proteomics Clin Appl

Specialty Biochemistry

Date 2018 Feb 25

PMID 29476593

Citations 6

Authors

Juhura G Almazi

Peter Pockney

Craig Gedye

Nathan D Smith

Hubert Hondermarck

Nicole M Verrills

Matthew D Dun

Affiliations

Soon will be listed here.

Abstract

Background: Optimized blood collection tubes (BCT) have been developed to expand the utility of plasma cell-free DNA (cfDNA) and are in clinical use. The appropriateness of plasma collected and stored in these tubes for proteomic analysis is unknown.

Methods: Paired blood samples were collected in BCT and traditional K3EDTA (EDTA) tubes from healthy controls and from colorectal cancer (CRC) patients before and after surgery, and stored for between 45 min and 48 h at room temperature. Plasma proteins were analyzed following high-abundant plasma protein depletion in quantitative discovery and targeted proteomics by liquid chromatography tandem-mass spectrometry (LC-MS/MS).

Results: BCT reduced cellular protein contamination in healthy controls over time, and increased the number of high confident low-abundant protein identifications in CRC blood samples compared to matched samples collected in EDTA tubes. The known CRC plasma protein biomarker, carcinoembryonic antigen (CEA), showed elevated levels across patients pre-operatively when collected and stored in BCT compared to EDTA tubes. Emerging CRC biomarkers, Dickkopf-3 (DKK3) and Gelsolin (GSN), showed elevated levels pre-operatively when collected in BCT.

Conclusions: Optimized BCT are appropriate for low-abundant plasma protein analysis and can be used with confidence for clinical proteomics.

Citing Articles

Mass Spectrometric Detection of Formaldehyde-Crosslinked PBMC Proteins in Cell-Free DNA Blood Collection Tubes.

Roth D, Molina-Franky J, Williams J, Kalkum M Molecules. 2023; 28(23).

PMID: 38067609 PMC: 10708122. DOI: 10.3390/molecules28237880.

2D-DIGE-MS Proteomics Approaches for Identification of Gelsolin and Peroxiredoxin 4 with Lymph Node Metastasis in Colorectal Cancer.

Huang C, Lee K, Tung S, Huang W, Teng C, Lee K Cancers (Basel). 2022; 14(13).

PMID: 35804959 PMC: 9265116. DOI: 10.3390/cancers14133189.

Correlation of Repeat Measurements of 27 Candidate Protein Markers for Colorectal Cancer Screening Taken Three Years and Multiple Freeze-Thaw Cycles Apart.

Bhardwaj M, Schrotz-King P, Brenner H Life (Basel). 2022; 12(3).

PMID: 35330110 PMC: 8949042. DOI: 10.3390/life12030359.

Dynamic Landscape of Extracellular Vesicle-Associated Proteins Is Related to Treatment Response of Patients with Metastatic Breast Cancer.

Ruhen O, Qu X, Jamaluddin M, Salomon C, Gandhi A, Millward M Membranes (Basel). 2021; 11(11).

PMID: 34832109 PMC: 8619728. DOI: 10.3390/membranes11110880.

Characterization of Plasma Cell-Free DNA Integrity Using Droplet-Based Digital PCR: Toward the Development of Circulating Tumor DNA-Dedicated Assays.

Poulet G, Garlan F, Garrigou S, Zonta E, Benhaim L, Carrillon M Front Oncol. 2021; 11:639675.

PMID: 34094923 PMC: 8174096. DOI: 10.3389/fonc.2021.639675.

References

Faulkner S, Dun M, Hondermarck H . Proteogenomics: emergence and promise. Cell Mol Life Sci. 2015; 72(5):953-7. PMC: 11113406. DOI: 10.1007/s00018-015-1837-y. View

Sastre J, Maestro M, Puente J, Veganzones S, Alfonso R, Rafael S . Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol. 2008; 19(5):935-8. DOI: 10.1093/annonc/mdm583. View

Diaz Jr L, Williams R, Wu J, Kinde I, Hecht J, Berlin J . The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012; 486(7404):537-40. PMC: 3436069. DOI: 10.1038/nature11219. View

Rothwell D, Smith N, Morris D, Leong H, Li Y, Hollebecque A . Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample. Mol Oncol. 2015; 10(4):566-74. PMC: 4834815. DOI: 10.1016/j.molonc.2015.11.006. View

Fung K, Tabor B, Buckley M, Priebe I, Purins L, Pompeia C . Blood-based protein biomarker panel for the detection of colorectal cancer. PLoS One. 2015; 10(3):e0120425. PMC: 4368610. DOI: 10.1371/journal.pone.0120425. View

Norton S, Luna K, Lechner J, Qin J, Fernando M . A new blood collection device minimizes cellular DNA release during sample storage and shipping when compared to a standard device. J Clin Lab Anal. 2013; 27(4):305-11. PMC: 3748785. DOI: 10.1002/jcla.21603. View

Jones J, Wilcox B, Benz R, Babbar N, Boragine G, Burrell T . A Plasma-Based Protein Marker Panel for Colorectal Cancer Detection Identified by Multiplex Targeted Mass Spectrometry. Clin Colorectal Cancer. 2016; 15(2):186-194.e13. PMC: 8961700. DOI: 10.1016/j.clcc.2016.02.004. View

Murray H, Dun M, Verrills N . Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer. Expert Opin Drug Discov. 2017; 12(5):431-447. DOI: 10.1080/17460441.2017.1304377. View

Nanjappa V, Thomas J, Marimuthu A, Muthusamy B, Radhakrishnan A, Sharma R . Plasma Proteome Database as a resource for proteomics research: 2014 update. Nucleic Acids Res. 2013; 42(Database issue):D959-65. PMC: 3965042. DOI: 10.1093/nar/gkt1251. View

10.

Gallien S, Duriez E, Crone C, Kellmann M, Moehring T, Domon B . Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer. Mol Cell Proteomics. 2012; 11(12):1709-23. PMC: 3518128. DOI: 10.1074/mcp.O112.019802. View

11.

Rengarajan K, de Smet M, Wiggert B . Removal of albumin from multiple human serum samples. Biotechniques. 1996; 20(1):30-2. DOI: 10.2144/96201bm05. View

12.

Hassis M, Niles R, Braten M, Albertolle M, Witkowska H, Hubel C . Evaluating the effects of preanalytical variables on the stability of the human plasma proteome. Anal Biochem. 2015; 478:14-22. PMC: 4492164. DOI: 10.1016/j.ab.2015.03.003. View

13.

Qin J, Alt J, Hunsley B, Williams T, Fernando M . Stabilization of circulating tumor cells in blood using a collection device with a preservative reagent. Cancer Cell Int. 2014; 14(1):23. PMC: 3995911. DOI: 10.1186/1475-2867-14-23. View

14.

Goslin R, OBrien M, Steele G, Mayer R, Wilson R, Corson J . Correlation of Plasma CEA and CEA tissue staining in poorly differentiated colorectal cancer. Am J Med. 1981; 71(2):246-53. DOI: 10.1016/0002-9343(81)90125-x. View

15.

Diaz I, Nocon A, Mehnert D, Fredebohm J, Diehl F, Holtrup F . Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing. PLoS One. 2016; 11(11):e0166354. PMC: 5104415. DOI: 10.1371/journal.pone.0166354. View

16.

Almazi J, Pockney P, Gedye C, Smith N, Hondermarck H, Verrills N . Cell-Free DNA Blood Collection Tubes Are Appropriate for Clinical Proteomics: A Demonstration in Colorectal Cancer. Proteomics Clin Appl. 2018; 12(3):e1700121. PMC: 5947838. DOI: 10.1002/prca.201700121. View

17.

Su B, Shi H, Wan J . Role of serum carcinoembryonic antigen in the detection of colorectal cancer before and after surgical resection. World J Gastroenterol. 2012; 18(17):2121-6. PMC: 3342612. DOI: 10.3748/wjg.v18.i17.2121. View

18.

Alpert A . Hydrophilic-interaction chromatography for the separation of peptides, nucleic acids and other polar compounds. J Chromatogr. 1990; 499:177-96. DOI: 10.1016/s0021-9673(00)96972-3. View

19.

Fan N, Gao C, Wang C, Lv J, Zhao G, Sheng X . Discovery and verification of gelsolin as a potential biomarker of colorectal adenocarcinoma in the Chinese population: Examining differential protein expression using an iTRAQ labelling-based proteomics approach. Can J Gastroenterol. 2012; 26(1):41-7. PMC: 3275404. DOI: 10.1155/2012/645218. View

20.

Spindler K, Pallisgaard N, Andersen R, Brandslund I, Jakobsen A . Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer. PLoS One. 2015; 10(4):e0108247. PMC: 4395277. DOI: 10.1371/journal.pone.0108247. View